Cargando…

Landscape of Health-Related Quality of Life in Patients With Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy: A Systematic Literature Review

OBJECTIVES: Pancreatic resection is associated with postoperative morbidity and reduced quality of life (QoL). A systematic literature review was conducted to understand the patient-reported outcome measure (PROM) landscape in early-stage pancreatic cancer (PC). METHODS: Databases/registries (throug...

Descripción completa

Detalles Bibliográficos
Autores principales:	Macarulla, Teresa, Hendifar, Andrew E., Li, Chung-Pin, Reni, Michele, Riess, Hanno, Tempero, Margaret A., Dueck, Amylou C., Botteman, Marc F., Deshpande, Chinmay G., Lucas, Eleanor J., Oh, Do-Youn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077976/ https://www.ncbi.nlm.nih.gov/pubmed/32132518 http://dx.doi.org/10.1097/MPA.0000000000001507

Ejemplares similares

Safety of adjuvant CDK4/6 inhibitors during the COVID-19 pandemic
por: Pfeiler, Georg, et al.
Publicado: (2022)

Neoadjuvant chemoradiation compared to neoadjuvant radiation alone and surgery alone for Stage II and III soft tissue sarcoma of the extremities
por: Curtis, Kelly K, et al.
Publicado: (2011)

Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial
por: Tempero, Margaret A., et al.
Publicado: (2023)

Population‐level evidence of survival benefits of patient‐reported outcome symptom monitoring software systems in routine cancer care
por: Basch, Ethan, et al.
Publicado: (2020)

The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
por: Wu, Dawei, et al.
Publicado: (2022)

Influence of Adjuvant Radiotherapy Timing on Survival Outcomes in High-Risk Patients Receiving Neoadjuvant Treatments
por: Cao, Lu, et al.
Publicado: (2022)

A Comparison of Clinicopathologic Outcomes Across Neoadjuvant and Adjuvant Treatment Modalities in Resectable Gastric Cancer
por: Anderson, Eric, et al.
Publicado: (2021)

Adjuvant and neoadjuvant therapies in melanoma
por: Lim, Kok Haw Jonathan, et al.
Publicado: (2020)

Evaluation of Therapeutic Strategies to Reduce the Number of Thrombotic Events in Patients With Polycythemia Vera and Essential Thrombocythemia
por: Tremblay, Douglas, et al.
Publicado: (2021)

An observational study to examine changes in metabolic syndrome components in patients with breast cancer receiving neoadjuvant or adjuvant chemotherapy
por: Dieli‐Conwright, Christina M., et al.
Publicado: (2016)

Epigenetic Biomarkers in Colorectal Cancer Patients Receiving Adjuvant or Neoadjuvant Therapy: A Systematic Review of Epidemiological Studies
por: Barchitta, Martina, et al.
Publicado: (2019)

Neoadjuvant and Adjuvant Therapy in Intrahepatic Cholangiocarcinoma
por: Chen, Xing, et al.
Publicado: (2022)

Neoadjuvant and adjuvant therapy in esophageal cancer
por: Weiss, Jennifer A., et al.
Publicado: (2023)

Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development
por: Geyer, Holly L., et al.
Publicado: (2015)

Treatment times in breast cancer patients receiving neoadjuvant vs adjuvant chemotherapy: Is efficiency a benefit of preoperative chemotherapy?
por: Melchior, Nicole M., et al.
Publicado: (2020)

Proper adjuvant therapy in patients with borderline resectable and locally advanced pancreatic cancer who had received neoadjuvant FOLFIRINOX
por: Choi, Jin Ho, et al.
Publicado: (2022)

Neoadjuvant and adjuvant therapy for gastrointestinal stromal tumors
por: Iwatsuki, Masaaki, et al.
Publicado: (2018)

Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma
por: Akateh, Clifford, et al.
Publicado: (2019)

Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant
por: Yang, Chang, et al.
Publicado: (2020)

Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC
por: Yi, Chengxiang, et al.
Publicado: (2019)

Adjuvant and Neoadjuvant Treatments for Resectable Hepatocellular Carcinoma
por: Crook, Christiana J., et al.
Publicado: (2023)

Patient reported symptoms associated with quality of life during chemo‐ or immunotherapy for bladder cancer patients with advanced disease
por: Taarnhøj, Gry A., et al.
Publicado: (2020)

Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who have or have not received neoadjuvant chemotherapy for advanced ovarian cancer
por: Meghal, Trishala, et al.
Publicado: (2019)

Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma
por: Van Cutsem, Eric, et al.
Publicado: (2020)

Online yoga in myeloproliferative neoplasm patients: results of a randomized pilot trial to inform future research
por: Huberty, Jennifer, et al.
Publicado: (2019)

The impact of systematic assessment for adverse events on unscheduled hospital utilization in patients receiving neoadjuvant or adjuvant chemotherapy: A retrospective multicenter study
por: Kim, Jwa Hoon, et al.
Publicado: (2021)

Can adjuvant radiotherapy be omitted for oral cavity cancer patients who received neoadjuvant therapy and surgery? A retrospective cohort study
por: Ju, Wutong, et al.
Publicado: (2023)

Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC
por: Walia, Anushka, et al.
Publicado: (2023)

Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score
por: Langlais, Blake T., et al.
Publicado: (2021)

Gastric Perforation in a Patient Receiving Neoadjuvant Chemoradiotherapy
por: Chen, Hui, et al.
Publicado: (2015)

The role of neoadjuvant and adjuvant treatment for adenocarcinoma of the upper gastrointestinal tract
por: Matuschek, C, et al.
Publicado: (2011)

Designing adjuvant treatment based on biological measurements in the neoadjuvant setting
por: Smith, Ian E, et al.
Publicado: (2010)

Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment
por: Ribeiro, J., et al.
Publicado: (2013)

Current treatment of early breast cancer: adjuvant and neoadjuvant therapy
por: Miller, Elizabeth, et al.
Publicado: (2014)

Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma
por: Wysocka, Olga, et al.
Publicado: (2016)

Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant Therapy
por: Ng, Gary, et al.
Publicado: (2022)

Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial
por: Eiger, Daniel, et al.
Publicado: (2020)

Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study
por: Mikhael, Joseph, et al.
Publicado: (2018)

RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer
por: Moreno-Aspitia, Alvaro, et al.
Publicado: (2013)

Prognostic Effect of the Dose of Radiation Therapy and Extent of Lymphadenectomy in Patients Receiving Neoadjuvant Chemoradiotherapy for Esophageal Squamous Carcinoma
por: Pai, Chu-Pin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j27b9db8ldpt66m20b9m1tpcc2